NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 287 filers reported holding NOVOCURE LTD in Q3 2020. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $738,000 | -59.9% | 9,718 | -63.3% | 0.04% | -49.4% |
Q2 2022 | $1,840,000 | +217.2% | 26,480 | +278.6% | 0.09% | +178.1% |
Q1 2022 | $580,000 | -70.2% | 6,995 | -73.0% | 0.03% | -55.6% |
Q4 2021 | $1,945,000 | +58.0% | 25,902 | +144.4% | 0.07% | +12.5% |
Q3 2021 | $1,231,000 | +67.5% | 10,600 | +220.0% | 0.06% | +100.0% |
Q2 2021 | $735,000 | -28.6% | 3,312 | -57.5% | 0.03% | -43.9% |
Q1 2021 | $1,030,000 | +302.3% | 7,789 | +238.7% | 0.06% | +103.6% |
Q3 2020 | $256,000 | -18.5% | 2,300 | -56.6% | 0.03% | -46.2% |
Q2 2020 | $314,000 | -54.8% | 5,300 | -48.5% | 0.05% | -38.1% |
Q1 2020 | $694,000 | +87.1% | 10,300 | +134.1% | 0.08% | +180.0% |
Q4 2019 | $371,000 | -71.3% | 4,400 | -74.6% | 0.03% | -62.0% |
Q3 2019 | $1,294,000 | +82.8% | 17,300 | +54.5% | 0.08% | +29.5% |
Q2 2019 | $708,000 | – | 11,200 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |